Skip to main content

Peer Review reports

From: Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance

Original Submission
10 Jan 2023 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
26 Feb 2023 Reviewed Reviewer Report
6 Mar 2023 Reviewed Reviewer Report
10 Mar 2023 Reviewed Reviewer Report
10 Apr 2023 Author responded Author comments - Toshihiko Minegishi
Resubmission - Version 4
10 Apr 2023 Submitted Manuscript version 4
24 Apr 2023 Reviewed Reviewer Report
5 May 2023 Reviewed Reviewer Report
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
8 May 2023 Editorially accepted
20 Jun 2023 Article published 10.1186/s12885-023-10930-2

You can find further information about peer review here.

Back to article page